New cocktail targets Hard-to-Treat lymphoma

NCT ID NCT03458260

Completed Disease control Sponsor: The Lymphoma Academic Research Organisation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of the drug pixantrone plus three other medicines (rituximab, ifosfamide, and etoposide) in 74 adults with a fast-growing type of lymphoma that had returned or not responded to treatment. The goal was to see how many patients had their tumors shrink or disappear after two cycles. The results could point to a new option for people who have run out of standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pixantrone (Pixuvri) combined with rituximab, ifosfamide, and etoposide
What this could lead to: If successful, this combination could offer a new treatment option for patients with aggressive non-Hodgkin lymphoma who have not responded to prior therapy.
What could go wrong: This is a small, early-phase (Phase 2) study with no comparison group, so results may not be definitive. The treatment involves chemotherapy drugs with known side effects like infection and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aggressive B-cell non-Hodgkin lymphoma diffuse large B-cell lymphoma follicular lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGGRESSIVE NON-HODGKIN LYMPHOMA

Contacts and locations

Show contact details

Locations

AZ Sint Jan

Bruges, Belgium
CH d'Avignon

Avignon, France
CH de Cornouaille

Quimper, France
CHRU de Lille

Lille, France
CHU Jean Minjoz

Besançon, France
CHU Lyon Sud

Lyon, France
CHU de Poitiers

Poitiers, France
CHU de Rouen

Rouen, France
CHU de Strasbourg

Strasbourg, France
CHU de Tours

Tours, France
CHU de la Conception

Marseille, France
Centre Hospitalier Annecy Genevois

Pringy, France
Centre Hospitalier William Morey

Chalon-sur-Saône, France
Centre Hospitalier de Jolimont

Haine-Saint-Paul, Belgium
Centre Hospitalier de la Côte Basque

Bayonne, France
Centre Lacassagne

Nice, France
Clinique Victor Hugo

Le Mans, France
Hopital La Pitié Salpétriere

Paris, France
Hôpital Haut-Lévèque

Bordeaux, France
Hôpital Robert Debré

Reims, France
Hôpital St louis

Paris, France
Institut Jules Bordet - Centre des tumeurs de l'ULB

Brussels, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.